Novogen licenses phase 2 - ready molecule GDC-0084 (Swings & Roundabouts ep. 033)

In late 2016, Novogen announced that it had in-licensed a drug from Genentech, a subsidiary of Roche. The drug, a small molecule phosphoinositide-3-kinase (PI3K) inhibitor, called GDC-0084, targets Glioblastoma Multiforme (GBM), the most common form of primary brain cancer, two thirds of whom are largely unresponsive to existing pharmaceutical treatments.